Due to their established effect on multiple tumour-related kinases such as the EGFR family members [33], Ibrutinib and AVL-292 have been experimentally proved useful in solid cancers such as glioblastoma, lung and breast carcinomas [34–39] and are now in clinical trials for EGFR-mutated NSCLC (https://clinicaltrials.gov/ct2/show/NCT02321540?term=ibrutinib&cond=NSCLC&rank=2) and HER2-amplified metastatic breast cancer (https://clinicaltrials.gov/ct2/show/NCT03379428?ter=ibrutinib&cond=Breast+Cancer&rank=1). The gene discussed is EGFR; the disease is cancer.